Novavax (NVAX) vs Windward Bio Group (WWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Windward Bio Group is the larger company by market cap ($1.45 billion vs $1.23 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVAX | WWB |
|---|---|---|
| Share price | $7.47 | $24.29 |
| Market cap | $1.23B | $1.45B |
| 1-day change | -3.24% | +1.15% |
| YTD return | +11.16% | — |
| 1-year return | +15.46% | — |
| 5-year return | -96.57% | — |
| EPS (TTM) | $-0.52 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.12B | — |
| Revenue growth (YoY) | +64.69% | — |
| Net income (latest FY) | $440.30M | — |
| Gross margin | 93.50% | — |
| Operating margin | 40.30% | — |
| Net margin | 39.19% | — |
| 52-week high | $13.39 | $33.99 |
| 52-week low | $6.36 | $18.35 |
| Distance from 52-week high | -44.21% | -28.55% |
| Analyst consensus | buy | — |
| Avg. price target upside | +88.89% | — |
| Average volume | 6.67M | 434.33K |
| Shares outstanding | 165.01M | 59.58M |
| Employees | 749 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
About Windward Bio Group
WWB stock →Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees
NVAX vs WWB FAQ
Which is bigger, Novavax or Windward Bio Group?
Windward Bio Group (WWB) is larger, with a market capitalization of $1.45B compared with $1.23B for Novavax (NVAX).
Are Novavax and Windward Bio Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.